Please assess the completion status of the following clinical trial:

Trial Title: CNS10-NPC-GDNF for the Treatment of ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of ALS (Lab-supported Probable, Probable or Definite EI Escorial Criteria)~2. Duration of symptoms ≤ 36 months~3. Progressive weakness in lower extremities, with EMG supported evidence of denervation in both lower extremities.~4. Forced Vital Capacity \>60% of predicted normal in supine.~5. Male/Female; Age: 18 and older~6. Able to provide Informed Consent~7. Be geographically accessible to the study site and able to travel to study site for required visits~8. Have caregiver to assist in the transportation and care required by participation in the study~9. Not taking riluzole or on a stable dose for ≥ 30 days~10. For women of child bearing capacity, negative pregnancy test prior to surgery~11. Medically able to undergo thoracolumbar laminectomy or laminoplasty as determined by the site PI and Neurosurgeon~12. Medically able to tolerate the immunosuppression regimen as determined by the site PI~Exclusion Criteria:~1. Using invasive ventilatory assistance~2. Diagnosis of another active or unstable medical illness that may interfere with study participation at discretion of PI~3. Presence of any of the following conditions:~   1. Current drug or alcohol abuse~  2. Any known immunodeficiency syndrome~  3. Unstable medical condition~  4. Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening~4. Persons of child bearing capacity not willing to practice birth control~5. Receiving any investigational device/biologic/drug in past 30 days or any previous exposure to stem cell therapy~6. Any condition in the lower extremities which precludes serial strength testing~7. Any condition that the Neurosurgeon feels may pose complications for the surgery~8. Any condition or ALS disease phenotype that the site PI feels may interfere with participation in the study or in the interpretation of study endpoints

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stem cell implantation (Type: EXPERIMENTAL): Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).